RCT: Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in head and neck cancer (PARADIGM- a phase 3 trial).

Source: Lancet Oncology Area: News PARADIGM is a multicentre open-label phase 3 study comparing the use of docetaxel, cisplatin, and fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin-based concurrent chemoradiotherapy alone in patients with locally advanced head and neck cancer. One hundred and forty five patients were randomly assigned in a 1:1 ratio to receive either induction chemotherapy with three cycles of TPF followed by concurrent chemoradiotherapy with either docetaxel or carboplatin, or concurrent chemoradiotherapy alone with two cycles of bolus cisplatin. The primary endpoint was overall survival.   After a median follow-up period of 49 months the following results were reported:   . 41 patients had died-20 in the induction chemotherapy followed by chemoradiotherapy group and 21 in the chemoradiotherapy alone group. . 3-year overall survival was 73% (95% CI 60-82) in the induction therapy followed by chemoradiotherapy group and ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news